Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TENAX THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for TENAX THERAPEUTICS, INC.

TENX

TENAX THERAPEUTICS, INC.

About TENAX THERAPEUTICS, INC.

Tenax Therapeutics is a clinical-stage pharmaceutical company focused on developing cardiopulmonary therapies. Its primary efforts include advancing levosimendan for pulmonary hypertension in HFpEF patients and exploring imatinib for pulmonary arterial hypertension. The company leverages existing approved drugs with established safety profiles, employing clinical insights and expert-led research to target unmet medical needs in cardiopulmonary diseases. It relies on strategic partnerships, proprietary IP, and regulatory pathways to develop and commercialize innovative treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TENAX THERAPEUTICS, INC.

1
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports $15.7 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports 189% Increase in Operating Expenses and $52.6 Million Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports $15.8 Million Net Loss in Latest Quarter, Increases Focus on Levosimendan

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports $10.8 Million Net Loss and Increased Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports $10.4 Million Net Loss and $111.4 Million Cash Reserves for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports 137% Increase in Operating Expenses and Raises $125 Million for Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TENAX THERAPEUTICS, INC. Tenax Therapeutics Reports Significant Financial Developments, Including Cash Infusion and Increased Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments